 |
|
|
| |
RUBY-I: Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in Non-Cirrhotic HCV Genotype 1-Infected
Patients With Severe Renal Impairment or End-Stage Renal Disease
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Paul J Pockros1, K Rajender Reddy2, Parvez S Mantry3, Eric Cohen4, Michael Bennett 5, Mark S Sulkowski6, David Bernstein7, Daniel E Cohen4, Nancy S Shulman4, Deli Wang4, Amit Khatri4, Manal Abunimeh4, Thomas Podsadecki4, Eric Lawitz8
1Scripps Clinic and Scripps Translational Science Institute, La Jolla, California, United States; 2University of Pennsylvania, Philadelphia, Pennsylvania, United States; 3The Liver Insti tute at Methodist Dallas, Dallas, Texas, United States; 4AbbVie Inc., North Chicago, Illinois, United States; 5Medical Associates Research Group, San Diego, California, United States; 6Johns Hopkins University, Baltimore, Maryland, United States; 7North Shore University Hospital, Manhasset, New York, United States; 8The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, United States
|
| |
|
|
|
|
|
